Personalized Medicine: The Future of Health Care by Meiliana, Anna et al.
 127
Personalized Medicine: The Future of Health Care (Meiliana A, et al.)Indones  Biomed J. 2016; 8(3): 127-46DOI: 10.18585/inabj.v8i3.271
Personalized Medicine: The Future of Health Care
Anna Meiliana1,2,, Nurrani Mustika Dewi1,2, Andi Wijaya1,2,3
1Postgraduate Program in Clinical Pharmacy, Padjadjaran University, Jl. Eijkman No.38, Bandung, Indonesia
2Prodia Clinical Laboratory, Jl. Cisangkuy No.2, Bandung, Indonesia  
3Postgraduate Program in Clinical Biochemistry, Hasanuddin University, Jl. Perintis Kemerdekaan Km.10, Makassar, Indonesia
Corresponding author. E-mail: anna.meiliana@prodia.co.id
Received date: Oct 30, 2016; Revised date: Dec 5, 2016; Accepted date: Dec 15, 2016
BACKGROUND: Most medical treatments have been designed for the “average patients.” As a result of this “one-size-fits-all-approach,” treatments can 
be very successful for some patients but not for others. The 
issue is shifted by the new innovation approach in diseases 
treatment and prevention, precision medicine, which takes 
into account individual differences in people’s genes, 
environments, and lifestyles. This review was aimed to 
describe a new approach of healthcare performance strategy 
based on individual genetic variants.
CONTENT: Researchers have discovered hundreds of 
genes that harbor variations contributing to human illness, 
identified genetic variability in patients’ responses to 
different of treatments, and from there begun to target the 
Abstract
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genes as molecular causes of  diseases. In addition, scientists 
are developing and using diagnostic tests based on genetics 
or other molecular mechanisms to better predict patients’ 
responses to targeted therapy. 
SUMMARY: Personalized medicine seeks to use advances 
in knowledge about genetic factors and biological 
mechanisms of disease coupled with unique considerations 
of an individual’s patient care needs to make healthcare 
more safe and effective. As a result of these contributions to 
improvement in the quality of care, personalized medicine 
represents a key strategy of healthcare reform.
KEYWORDS: precision, medicine, genomic, proteomic, 
metabolomic
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Introduction
Since the genome project was conducted, we know that every 
individual has his/her own unique variations of the human 
genome, due to the combination of genetic variations and 
environment influence. Not all of those genome variations 
affect their state of health, but they could manifest in different 
individual responses to drugs treatment. Senior government 
officials, industry leadership, health care providers, followed 
by the public within the last decade, have testimony a steady 
embrace of genomic and personalized medicine. In genomic 
medicine, information from genomes and their derivatives 
(RNA, proteins, and metabolites) is used to guide medical 
decision making. Genomic medicine is a key component of 
personalized medicine, which is a rapidly advancing field of 
health care based on each person’s unique clinical, genetic, 
genomic, and environmental information.(1) 
 Along the continuum from health to disease, genome 
information can provide DNA-based assessment for 
common complex disease, molecular indication for cancer 
diagnosis and prognosis, genome-guided therapy, dose 
selection, and much more for personal health care. This 
is moving fast in technological development, social and 
information revolution which will affect the health care way 
of thinking.(1) In simple word, genomic medicine is using 
information from genomes, either human or other organisms, 
and their derivatives to guide the medical decision making. 
Furthermore, it is now possible to examine a person’s 
entire genome (or a fraction of it as you need) to assess 
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individualized risk prediction and treatment decisions. 
Many patterns of gene expression across the entire genome 
are also now readily assayed. Thus, health and disease states 
can now be characterized by their molecular fingerprints to 
develop meaningful stratifies for patient populations and 
to elucidate mechanistic pathways based on genome-wide 
data.(1)
 Personalized medicine is a broad and rapidly advancing 
field of health care that is informed by each person’s 
unique clinical, genetic, genomic, and environmental 
information. Health care with personal medicine encircled 
could integrate and coordinate the evidence-based approach 
for patient care individually from health to disease. 
Personalized medicine needs multidisciplinary health care 
teams to reach its goal of promoting health and wellness, 
patients education and satisfaction, also disease prevention, 
diagnose and treatment. By genomic medicine, personalized 
medicine could be understanding molecular pathways of 
disease, therefore optimal health care strategies could be 
established in the earliest stage, and optimal medical care 
could be reached for better outcomes for each individual, 
to include treatments, medication types and dosages, 
and/or  prevention strategies may differ  from  person to 
person, resulting  in  an  unprecedented  customization of 
patient care.(1) Personalized medicine, also referred to 
as individualized or precision medicine, is the practice of 
tailoring medical treatment to the individual characteristics 
of each patient.(2,3) Both physicians and patients highly 
expecting this enormous potential personalized medicine to 
give better clinical outcomes by moving away from a one-
size-fits-all approach to a treatment strategy that are most 
likely to benefit each individual.(4)
On January 30, 2015, US President, Obama, announced 
funding for an Initiative in Precision Medicine (1) less than 
3 years after a National Academy of Sciences committee 
report (2) made clear just how such an initiative could 
accelerate progress in medical care and research. By 
understanding precisely, what the distinguishing features of 
specific subgroups of patients are, we can better individualize 
therapies. This led to rapid improvement in technology that 
drives genetic discovery in human disease. We now can 
monitor our personal health and environment easier than 
ever, just using wearable activity trackers to metagenomic 
sequencing and direct-to-consumer genetic testing.
Building The Foundation for Genomic in Personalized Medicine 
 Human physiology is complex. There are some cases 
where the patient’s symptoms cannot be ascertained, or the 
clinicians cannot gather enough data to decide, and these 
led to a guesswork inherent in the practice, that reduces 
the treatment strategies. The important contributor to this 
complexity is genetic. Though showing a similar set of 
symptoms, distinct genetic variants cause different respond 
to treatments. Without a mechanism to determine the 
underlying genetic cause of a set of symptoms, it might not be 
possible to determine which treatment will be most effective 
a priori.(7) Even when you know the cause of a condition, 
variants of unrelated genetic can affect treatment efficacy by 
altering the drugs pharmacokinetic. For example, patients 
with some genetic variants who are treated with traditional 
doses of azathioprine, an immunosuppressive drug for an 
extended period were known at risk of developing life-
threatening myelosuppression because the genetic variant 
prevent the drug from being properly metabolized.(8)
 The  goal  of  precision medicine  is  to  enable 
clinicians to quickly, efficiently and accurately predict 
the most  appropriate  course  of  action  for  a  patient. 
To achieve this, clinicians are given tools, in the form of 
tests and information-technology support, that are both 
compatible with their clinical workflow and economically 
feasible to deploy in the modern health-care environment. 
These tools  help  to simplify the process of managing 
the extreme biological  complexity  that  underlies human 
disease. Then, a precision-medicine ‘ecosystem’ that link 
clinicians, laboratories, research enterprises and clinical-
information-system developers together in new ways was 
developed  to support  the creation  and  clarification  of 
these  tools  (Figure 1). These efforts will create a foundation 
of a continuously learning health-care system which was 
hope to  accelerate  the  advance  of  precision-medicine 
techniques.(7)
 Clinical laboratories with their information systems 
facilitate interpretations consolidation into reports and alerts, 
and the results applied with the help of  Electronic Health 
Records (EHR) and associated systems, both when they are 
received and as the patient’s condition and knowledge of 
the variants evolve. Patient-facing infrastructure or ‘portals’ 
provide individuals with access to their genetic data and, 
if appropriate, the ability to decide how they should be 
used, including whether to participate in research. At 
present, much of this infrastructure is at a very early stage 
of development. However, the infrastructural foundation for 
precision medicine is beginning to emerge.
 Patients’ role in supporting precision medicine also 
important. The precision medicine can be tailored to the 
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Figure 1.  The precision-medicine ecosystem. The 
precision-medicine ecosystem contains building 
blocks that optimally connect patients, clinicians, 
researchers and clinical laboratories to one 
another.(7) (Adapted with permission from Nature 
Publishing Group).
unique genetic make-up of each patient, by gathering as 
much information as possible from individual patient.(7) 
Clinicians usually take a role in patients’ treatment order 
such tests for them.(8) Patients are obtaining an enlarge 
number of genetic results in the course of their care, and 
now they even can access direct-to-consumer testing, or 
through the help of someone who is not directly involved in 
their care.(7) 
 Clinicians gain access to patients’ genetic information 
through tests. Tests have two components: a technical 
component that focuses on identifying which variants are 
present in the patient; and an interpretive component in 
which the implications of identified variants are assessed. 
In most scenarios, genetic testing is performed to determine 
either the cause of a specific indication or the most 
appropriate treatment.(9) Genome and exome sequences 
are possible to be obtained and stored, to be reused for 
multiple assessments perform over time even before disease 
manifests so that they can be interpreted and reinterpreted as 
indication arise.
 EHRs are well positioned to be the apex of genetic 
information-technology support. They should serve as 
the clinician’s gateway to all of the patient’s information, 
including any genetic data. Information should be organized 
and displayed in a way that integrates with the clinician’s 
workflow and facilitates diagnostic and treatment decisions. 
EHR and related systems can also provide clinicians 
with electronic clinical-decision support that provides 
extra information about a genetic test or result through an 
e-resource or InfoButton that links to electronic resources 
such as websites or databases.(10,11) They can also issue 
pre-test and post-test pharmacogenomic warnings that 
highlight potentially adverse interactions between drugs and 
specific genetic variants. Pre-test will be suggested when 
a clinician is going to take an action that needs a genetic 
assessment information, but the patient’s has no record of 
this assessment. Post-test alerts will be suggested when a 
clinician is going to take an action which is contraindicated 
with the patient’s genetic profile.(7)
 Clinical laboratories as the core of interpretative 
process provide either the evidence for individual variants 
and the case-level report with all potentially relevant 
variants in the context of the patient’s presentation. New 
variants often found while performing genome sequencing, 
which must then be assessed. Many established variants also 
need to be assessed as a new knowledge rise. Laboratories 
and clinicians share variant- and gene-level assessment to 
increase the quality and efficiency of the variant assessment 
process.(12-16) The ClinGen program is building an 
authoritative central resource for use in precision medicine 
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and  research  that  defines  the  clinical  relevance  of 
genomic variants.
 Several databases have been launched that share 
case-level data across broad disease areas. The National 
Center for Biotechnology Information (NCBI)’s database of 
Genotypes and Phenotypes places minimal restrictions on 
the types of case data that can be submitted and therefore 
serves as a generalized repository.(17) The International 
Cancer Genome Consortium (ICGC) and The Cancer 
Genome Atlas (TCGA) have each set up large repositories 
of somatic cancer sequencing data.(18,19) The American 
Society of Clinical Oncology (ASCO) is looking to 
incorporate the tracking of patient outcomes to enable a 
learning health care system in its CancerLinQ platform.(20)
One of the great challenges for 21st century medicine is 
to deliver effective therapies that are tailored to the exact 
biology or biological state of an individual to enable so-
called ‘personalized healthcare solutions.’ Ideally, before 
the therapy started, this would involve a patient evaluating 
system that provides clinicians about the individual’s correct 
drug and dose, or intervention. This evaluation concept 
approached on patient stratification, commonly according 
to some genetic features, be sub-classified to bio-features 
modeled in relation to the outcome. This stratification will 
be applied for personal therapy with a drug safety and 
efficacy model, as well as general healthcare involving 
optimized nutrition and lifestyle management.
 Systems biology provides us with a common 
language for both describing and modeling the integrated 
action of regulatory networks at many levels of biological 
organization from the subcellular through cell, tissue 
and organ right up to the whole organism. The relatively 
new science of molecular epidemiology concerns the 
measurement of the fundamental biochemical factors that 
underlie population disease demography and understanding 
‘the health of nations’ and this subject naturally lends it to 
systems biology approaches. Thus, personalized medicine 
and molecular epidemiological studies are certain to have 
a major  role  in  future  development  of  systems  biology 
(Figure 2).(21)
 Genetic variants predicted to severely disrupt protein-
coding genes, collectively  known  as loss-of-function 
(LoF)   variants,  are   of   considerable   scientific   and 
clinical interest.(22) Proteins form the structural fabric of 
cells and underpin all metabolic processes and regulatory 
Systems Biology
Figure 2. Relationships between systems biology, personalized 
healthcare and molecular epidemiology. Dotted lines indicate 
indirect connections or influences.(21) (Adapted with permission 
from Nature Publishing Group).
mechanisms. Protein properties, including abundance 
levels, protein-protein interactions, post-translational 
modifications subcellular localization patterns and protein 
synthesis and degradation rates, are all highly dynamic and 
can change rapidly during the course of biological processes, 
such as cell proliferation, cell migration, endocytosis and 
development. Therefore, understanding protein structure-
function relationships in cell biology not only requires the 
identification of proteins but also the detailed analysis of 
the protein properties that constitute the dimensions of the 
proteome.
 Several studies in cellular processes have involved 
multi-dimensional analysis of protein properties to 
understanding cell and tissue biology better. Many of these 
have been aided by developments in mass spectrometry 
(MS)-based analysis, enabling higher sensitivity and a 
higher dynamic range of quantification.(23-26) In addition, 
over the past decade, biochemical and cell biological 
fractionation, such as chromatography or centrifugation-
based separations, have increased in efficiency and 
resolution. Thus, multiple separations can now more easily 
be combined for sequential multidimensional proteome 
analysis (Figure 3).
 MS-based proteomics was now developed to enable 
the multiple properties measurements of thousands proteins, 
including their abundance, isoform expression, turnover rate, 
subcellular localization, post-translational modifications and 
interactions and will be completing with new data analysis, 
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Figure 3. Multidimensional proteomic analysis 
of cells and tissues. Proteins can have many 
different properties (dimensions) that are either 
largely physically (yellow shaded area), chemically 
(orange shaded area) or biologically (beige shaded 
area) relevant.(27) (Adapted with permission from 
Nature Publishing Group).
integration and visualization tools as well as data-sharing 
resources. Together, these advances in the multidimensional 
analysis of the proteome are transforming our understanding 
of various cellular and physiological processes.(27) This 
will not only be important to magnify our understanding of 
basic cellular physiology and regulation but also for future 
advances in medicine and drug development.
 Personalized healthcare and molecular epidemiology 
are thus effectively two sides of the same ‘systems biology 
coin’; the essential differences are with respect to the 
type  of  medical  endpoints  or  outcomes  that  are  to 
be modeled (Figure 2). Metabolomics offers a practical 
approach to measuring the metabolic end points that link 
directly to whole system activity and metabolic profiles 
are determined by both host genetic and environmental 
factors.(28) Metabolomics is an emerging field and is 
broadly defined as the comprehensive measurement of 
all metabolites and low-molecular-weight molecules in 
a biological specimen. Because metabolomics affords 
profiling of much larger numbers of metabolites than are 
presently covered in standard clinical laboratory techniques, 
and hence comprehensive coverage of biological processes 
and metabolic pathways, it holds promise to serve as an 
essential objective lens in the molecular microscope for 
precision medicine.(29) Practically, not alike genomic or 
proteomic methods, metabolomics presents a significant 
analytical challenge, due to its aim in measuring disparate 
physical molecule properties (e.g., ranging in polarity 
from very water soluble organic acids to very nonpolar 
lipids).(30) Accordingly, comprehensive metabolomic 
technology platforms typically take the strategy of dividing 
the metabolome into subsets of metabolites, often based 
on compound polarity, common functional groups, or 
structural similarity, and devise specific sample preparation 
and analytical procedures optimized for each, as illustrated 
in Figure 4. The metabolome is therefore measured as a 
patchwork of results from different analytical methods.
 Metabolomics evolve rapidly nowadays, aim for 
an ideal comprehensive measurements of all endogenous 
metabolites in a cell or body fluid, and providing a functional 
readout of human body’s physiological state. Hemostasis of 
key lipids, carbohydrates, or amino acids can change due to 
the genetic variants. Their involvement directly in metabolic 
conversion modification are not only expected to display 
much larger effect sizes, and also expected to provide access 
to the biochemical context of such variations, in particular 
when enzyme coding genes are concerned.(31) Now, 
metabolomics is on the level of technology refinement, and 
we are still determining what actually constitutes the human 
metabolome, while the expectation of small molecules 
finding in the human body exceeds 19,000.(32) This number 
includes not only metabolites directly linked to endogenous 
enzymatic activities encoded by the human genome, but 
also those derived from food, medications, the microbiota 
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Figure 4. Illustration of the liquid chromatography-MS (LC-MS)-based metabolomics platform used at the Broad Institute of MIT 
and Harvard.(29) (Adapted with permission from Cold Spring Harbour Laboratory Press). IPA: isopropanol; MeOH: methanol; AcCN: 
acetonitrile; RP/C8: C8 reversed phase; RP/C18: C8 reversed phase; HILIC: hydrophilic interaction chromatography.
that inhabit the body, and the environment. Our dependence 
on diet as a source for nine of the 20 amino acids for which 
there are codons in the human genome but no endogenous 
biosynthetic route is an example that highlights why it is 
important to account for “exogenous” metabolites in our 
study of the metabolome.(29)
 The discovery of specific markers for diseases and 
drug pharmacodynamics, as well as metabolite profiles, 
in relation to external environment and disease risk could 
enhance the potential of precision medicine. Current 
metabolomics technologies can enable more rapid discovery 
and validation of metabolic indicators of disease. Techniques 
used in metabolomics, such as liquid chromatography-
mass spectrometry (LC-MS), can routinely measure 
tens to hundreds of metabolites with excellent precision 
and are suitable for discovery studies in human cohorts. 
Confidence comes from experience with recent applications 
to find early metabolic indicators of disease in longitudinal 
cohorts years before symptoms are clinically apparent, for 
example, in pancreatic cancer (33), type 2 diabetes (34-36), 
memory impairment (37), and many other conditions. Many 
metabolomics studies provide novel view about relationship 
between diet and diseases, provoke applied work such as 
observing the association between elevated branched chain 
Human Phenotyping
amino acids and obesity to insulin resistance.(38) System 
biology genomic to phenotype is shown by Figure 5. 
A phenotypic abnormality is defined in medical settings as a 
deviation from normal morphology, physiology, or behavior, 
and good phenotyping is a cornerstone of a doctor’s daily 
work.(39) Progress in information technologies together 
with next-generation sequencing (NGS), proteomics, 
and metabolomics are bringing about a paradigm shift 
in translation research and clinical care. Physicians and 
patients in the future will allow accessing a large-scale 
data to help them stratifying and improving the medical 
treatments. Provided correct and up-to-date information with 
sufficiently detailed and accurate phenotypic description 
will support the best treatment selection.(40,41)
 The term “phenotype” used in medical context refers 
to some deviation from normal morphology, physiology, 
or behavior. This phenotype analysis plays a key role 
clinical and medical practice as well as research, but these 
descriptions in clinical notes or medical publications 
often were imprecise. Deep phenotyping can be defined 
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Figure 5. Genomic to phenotype (system biology).
as the precise and comprehensive analysis of phenotypic 
abnormalities where an individual assessment are performed 
for detail components of the phenotype observation and 
description.(42) 
 The International Standards for Cytogenomic Arrays 
Consortium has promoted standards for chromosomal 
microarray analysis and phenotypes and currently collected 
data on over 28,500 cytogenomic array investigations (43), 
and is thus one of the first examples of a Human Phenome 
Project covering a specific area of genetic medicine. The 
Personal Genome Project was aimed to involve 100,000 
informed consent-signed general public participants to 
share their genome sequence and some personal and 
phenotypic information. Here, a prototype project involving 
metabolomic phenotyping coupled to the targeted analysis 
of a set of genes known to be involved in metabolic 
disturbances is presented.(44)
 Deep phenotyping generally performed in such a way 
as to be computationally accessible. Using the common 
biological basis stratification, precision medicine intends to 
reconcile the best available care into the disease subclasses. 
These comprehensive discoveries and their translation 
into clinical care, critically need a computational resource 
to capture, store and exchange deep phenotypic data. A 
sophisticated algorithm will be required to integrate this 
deep phenotype data with genomic variation and additional 
clinical information.(42)
 A “traditional” method of retrieving phenotype data 
from the medical literature or ERH for computational 
analysis is text mining. However, the overwhelming 
majority of clinical descriptions in the medical literature are 
simply natural language text, and thus automated searching, 
analysis, and integration of medical information from 
databases such as PubMed remains challenging.(45) To 
overcome those limitations, a structured, comprehensive, 
and well-defined phenotyping terminology is established. 
The Human Phenotype Ontology (HPO), available at www.
human-phenotype-ontology.org, provides a set of more than 
11,000 terms describing human phenotypic abnormalities. 
They describe the concepts of human phenotypes as 
well as a logical (computational) representation of the 
interrelationships between the terms.(41)
 The rapid growth of sequencing technologies has 
greatly contributed to our understanding of human genetics. 
Yet, despite this growth, mainstream technologies have not 
been fully able to resolve the diploid nature of the human 
genome, including the method to determine allele-specific 
methylation patterns in a human genome and identify 
hundreds of differentially methylated regions that were 
previously unknown.(46) Besides differential methylation 
studies, haplotype information has applications in many 
areas of genomics, including (i) the analysis of disorders 
affected by compound heterozygosity, such as blistering 
skin (47), cerebral palsy (48), deafness (49) and others 
(50); (ii) population genetics, where population-specific 
haplotype blocks are currently resolved using lower-
accuracy statistical methods (51); (iii) the detection of 
structural variations, which has been shown to benefit 
from phase information (52); (iv) the matching of hosts 
and donors in organ transplantation based on the human 
leukocyte antigen (HLA) region of the genome (53); (v) the 
evolution of genomes across species (54).
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 To understand the relationship between genotype 
and phenotype, we need a haplotype-resolved information 
for the human genome, because we might find that a 
different configuration of exactly the same set of variants 
can sometimes result in different outcomes with regard to 
phenotype and disease susceptibility.(50) This information 
has typically been obtained by mapping sequence reads 
back to the human genome reference (55), and such methods 
cannot  be applied to  species  for  which  a  reference  genome 
is not available. Advanced NGS technology and numerous 
bio-informatics techniques (56-58) have been developed and 
applied to the production  and  analysis of large-scale human 
sequence data in many individuals (59-62) and international 
projects (63-67). However, NGS technology give a short-
read format of mixed DNA fragments derived from a pair 
of diploid chromosomes, and this posing challenges for 
determining haplotype information.(66)
 Several computational and experimental 
methodologies have been developed to obtain haplotype 
information, including (i) population-based statistical 
phasing by integration of unrelated individual data (63,67); 
(ii) trio-based  phasing  applying  Mendel’s  law  of 
inheritance  (68);  (iii) phasing by direct usage of sequence 
reads information (59); (iv) experimental phasing that 
includes the use of various forms of polymerase chain 
reaction (PCR), atomic force microscopy with carbon 
nanotubes (69) and hybridization of probes to single DNA 
molecules (70,71); (v) physical methods involving the 
initial preparation of haploid genomic material, for which 
the haplotype origin is distinguishable after sequencing 
(52,53,72). Stratified medicine could be simply defined as 
tailoring of medical treatment to the individual characteristics 
of each patient. It doesn’t mean the drugs or medical devices 
were created individually for each patient, but rather about 
classifying patients into a stratified subpopulation based 
on their uniqueness and their susceptibility (or severity 
of) a particular disease and their response to a specific 
treatment. Preventive or therapeutic interventions can then 
be concentrated on those who will benefit, sparing expense 
and side effects for those who will not”. It  also  involves 
the  development,  validation  and  use of companion 
diagnostics to achieve the best outcomes in the management 
of a patient’s disease or future prevention.(73)
 Exploiting continuing scientific advances in genomics, 
molecular biology and medical technologies to detect and 
classify diseases more objectively lies at the heart of stratified 
medicine. Many reports apply the term “stratification” 
for describing this molecular sub-classification of disease 
and disease susceptibility based on both biomarkers and 
phenotypic descriptions. It was crucial to note that this 
stratification is not limited to molecular technologies. Actual 
and future advances in these areas are leading to an increase 
in the efficiency and precision of drug use, dose selection 
and diagnostic discovery and development.(73)
 In earlier 2015, tech giant Apple announced the launch 
of its ResearchKit. The ResearchKit is a mobile platform 
that taps into the iPhone’s 700 million global users to find 
individuals interested in participating in human research 
studies. The first five apps included in the kit enable users 
to enroll in observational studies on Parkinson’s (mPower 
app), cardiovascular health (MyHeart Counts), breast cancer 
(Share The Journey), asthma (Asthma Mobile Health) and 
diabetes (GlucoSuccess). The studies are being run in 
conjunction with 17 different partner research institutions 
and foundations, many of which are US-based. ResearchKit 
is the latest of several ambitious initiatives that seek to 
harness the convergence of mobile technology, wearable 
sensors for measuring phenotypic markers, and highly 
sensitive technologies for measuring genomic, epigenetic, 
proteomic and metabolic markers in blood, stool and tissue. 
Ultimately, the harnessing of these technologies with 
computational platforms to store, share, filter and analyze 
the data will make it possible to collect markers of health 
and disease data for entire human populations, opening new 
possibilities for biomedical research.(74)
 Another strength of platforms driven by mobile 
technology is that they offer the ability to monitor phenotypes 
in a longitudinal manner. In the case of the mPower app, trial 
participants could track how a disease affects gait, tremors, 
mood, cognition, fatigue, speech and sleep on a daily 
basis. This gives a chance about revealing new informative 
patterns of markers regarding the disease progression and 
severity. Sufficient sample sizes was expected to facilitate 
an adequate statistical power analysis that may enhance 
our ability to stratify diseases, which are currently defined 
on the basis of imprecise symptoms/phenotypes, into more 
finely described subgroups. Indeed, a major aim of the 100K 
Wellness project (currently scaling up to 1,000 individuals) 
the Personal Genome Project, Human Longevity and the 
Google Baseline Study is to compare the transition of 
individuals from wellness to disease. This is significant 
because in many cases we are unclear as to what is meant 
by a ‘healthy person.’ Finer and more exact categorization 
of phenotypes will mean that we will have the potential to 
diagnose disease faster and earlier than before, which in 
itself is likely to make interventions more effective.(74)
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After decades of exploration, approximately 20 genes 
of inherited variations have been identified which affect 
about 80 medications and are actionable in the clinic. Some 
somatically acquired genetic variants direct the choice of 
‘targeted’ anticancer drugs for individual patients. The focus 
of current efforts for appropriate are shifting from discovery 
to the implementation of an evidenced-based strategy 
to improve the use of medications, thereby providing a 
cornerstone for precision medicine.(75) Pharmacogenomics 
focuses on the identification of genetic variants that influence 
drug effects, typically through alterations in pharmacokinetic, 
that is how the drug is absorbed, distributed, metabolized 
or eliminated, or pharmacodynamics, by modifying its 
target or by perturbing the biological pathways that shape 
a patient’s sensitivity to its pharmacological effects. Most 
genetic variations either inherited from parents or changed 
de novo identified in germline DNA, and alter the function 
of gene products. Differently, in cancer, patient’s response to 
the treatment was affected by both inherited and somatically 
acquired variants. In infectious diseases, genetic variation 
can affect a pathogen’s sensitivity to antimicrobial drugs. 
Genome interrogation technology for analytical approaches 
has come to advance, lead to the evolution of a discovery 
model from gene studies candidate to a new finding of 
agnostic genome-wide analyses in specific drug-response 
phenotypes patients population, for example, toxicity 
or desired pharmacological effects. In fact, the genome 
interrogation technologies currently are sufficiently robust 
that makes it harder to define the drug-response phenotype 
in pharmacogenomics research. Once a pharmacogenomic 
relationship has been discovered and validated, there are 
many obstacles to translating it into clinical practice. Such 
translation requires that effective, alternative therapy is 
available for those with ‘high-risk’ genotypes, as well as 
improvements to health care systems, structured approaches 
to guide prescribing (for example, algorithms), and 
implementation of point-of-care electronic clinical decision 
support, to make it feasible to utilize genetics appropriately 
to guide drug prescribing.(75)
 More than 1,200 individual molecular entities 
have been approved as drugs by the US Food and Drug 
Administration (FDA) (76), the European Medicines 
Agency (EMA) (77) or by  Japan’s Pharmaceuticals  and 
Medical Devices Agency (PMDA) (78).  Although  about 
15%  of  the  medications approved  by  the FDA and  EMA 
contain pharmacogenomic information on their label, 
Pharmacogenomics only a subset of  the  corresponding  pharmacogenes  is deemed actionable.(77,79) As summarized, medications 
have actionable germline pharmacogenetics. These 
correspond to Clinical Pharmacogenetics Implementation 
Consortium (CPIC) level A or B gene-drug pairs for which 
genetic information should or could be used to change the 
prescription pattern of the relevant drug.(80) In the United 
States, these medications constitute 18% of all prescriptions, 
which indicates that pharmacogenomically high-risk 
medications are slightly overrepresented in highly prescribed 
medications.(81) So far, only 16 of the roughly 19,000 
human genes are considered to be clinically actionable for 
germline pharmacogenomics.(80) Prescription medication 
are unlikely to be useful in most human germline genetic 
variation, as well as pharmacogenomics can not be useful 
enough for improving the prescription of the majority of 
drugs. However, for the relatively small set of medications 
where genomics can be actionable, more widely genetic 
testing and appropriately deploying of it in the clinic could 
optimize the prescribing.(75)
 Some barriers still be the obstacle in wide spreading 
the use of pre-emptive multigene panels to guide the drugs 
prescription, such as the lack of incentives for clinicians to 
conduct tests or implement procedures that might prevent 
adverse events. There are relatively few studies that prove 
the cost-effectiveness of pharmacogenetic testing.(82) 
Although a multigene panel approach is less expensive than 
ordering tests for one pharmacogene at a time, there are no 
data to assess the cost-effectiveness of the panel approach 
when implemented early on in life and used throughout a 
patient’s lifetime. Another barrier is the fact that financial 
reimbursement for preventive-medicine services or for pre-
emptive screening usually was not provided by most health-
care system.(83,84)
 As deep sequencing becomes more widespread, 
further variants will be discovered in pharmacogenes.(85) 
The   challenge   will   be   to   catalog  and   annotate 
these variants. Given the importance of rare variants for 
both inherited (86) and cancer-related pharmacogenes, 
publicly available and easily updatable resources such 
as PharmGKB, ClinGen and ClinVar will be essential for 
providing the computational clinical-decision support in 
health care record systems with up-to-date recommendations 
that are based on genetic-test results.(87-89) Clinicians are 
accustomed to making prescribing decisions on the basis of 
patient characteristics such as age, kidney or liver function, 
drug-drug interactions and personal preferences. This data 
should be compiled with optimal clinical-decision support to 
create a well-organized compilation of one's characteristics 
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matched with evidenced-based choices on medications and 
doses. Pharmacogenomics was hope to be a component 
of evidence-based precision medicine, with the improved 
of clinical-decision support and pharmacogenomic testing 
continues to grow accelerate with clinical implementation 
of pharmacogenomics.
Next generation technologies (NGT) proposed huge 
improvements not only in cost efficiency, accuracy, 
robustness, but also in the amount of information they 
provide. Unique combination of microarrays together with 
high-throughput sequencing platforms, digital droplet 
PCR, and other technologies will offer a more desirable 
performance. As stronger evidence of genetic testing’s 
clinical utility influences patterns of patient care, demand 
for NGT testing is increasing. This will challenge the clinical 
laboratories to provide NGT-based protocols aligned with 
the traditional tests, while the urgency, clinical importance, 
and breadth of application in molecular oncology, as well 
as more integration of genetic tests into synoptic reporting 
keep increasing.(90)
 The advances in NGT technologies coalesced with 
the accelerated discovery of the genetic basis of human 
diseases in parallel feeding the molecular genetic testing 
to be rapidly expanding, and makes possible to convert 
cumbersome Sanger-based assays to be a streamlined and 
less costly, comprehensive targeted gene panels with the 
application of whole exome sequencing (WES) and whole 
genome sequencing (WGS) so that molecular diagnosticians 
could easily examine the known genes responsible for 
target phenotype(s) and to identify previously unrecognized 
causes for the heritable disorder for which the test was 
indicated. Such testing also identifies incidental findings, or 
off-target sequence alterations unrelated to the reason for 
testing, that could affect the participant’s health now or in 
the future. Readily interpretable test reports, however, still 
not easy to produce due to exome and genome sequencing 
which increasing the test complexity. In addition, new 
“meaningful use” components of Medicare and Medicaid 
EHR Incentive Programs (from Centers for Medicare and 
Medicaid Services, in 2013) permit patients to directly 
access results from all clinical laboratory tests, which create 
a new audience that may struggle to interpret complex 
genomic reports. With any rapidly evolving technology 
comes growing pains and caveats. Clinical laboratories 
that report results from exome or genome sequence data 
Personalized Medicine Toolbox
must be able to communicate the outcomes of those efforts 
effectively.(91)
 The first human genome costs $3 billion and took 
13 years to sequence; today such an undertaking costs 
closer to $1,000 and takes only days, making large-scale 
genetic analysis feasible and affordable. Short- and long-
read sequencers all the time is known as an established 
workhorses in biomedical research, and now their uses 
are expanding into clinical applications and beyond. Most 
notably, the combination of high-throughput genotyping 
with measurements of other markers of health and disease is 
opening up the area of precision medicine.(92)
 Although NGS (Table 1) platforms have become an 
established tool in the research arena, a highly anticipated 
area of growth in the research market is the large-scales 
genotyping of populations. In 2012, UK Prime Minister 
David Cameron announced a project to sequence the 
genome up to 100,000 people and use their genomic 
information in treatment and studies of cancer and rare 
diseases. This project will be run by Genomics England, a 
company established in July 2013 by the UK Department 
of Health, together with Illumina for sequencing and 
data analysis pipelines instruments and infrastructure 
provider. They selected four companies in July 2015 to 
work on interpreting genomic data from the first 8,000 
patients participating in the project: WuXi NextCODE for 
interpreting variants found in individuals with both cancer 
and rare diseases, Congenica and Omicia for rare-disease 
interpretation, and NanHealth for oncology. The study will 
last 3 years; if it is successful, Illumina anticipates that it 
will lead to an expansion of the effort to sequence a greater 
proportion of the UK population.(92)
 Lots of passionate scientists with their own interest 
enrich the continuity progress in science with diverse sparks, 
discoveries, or even disruptive. One interesting disruptive 
technology is the capillary sequencing, also known as Sanger 
sequencing.(93) It enabled the initial sequencing of the 
human genome (55,94) and led to the second Noble prize for 
the late Dr. Fred Sanger in 1980 (http://www.nobelprize.org/
nobel_prizes/chemistry/laureates/1980/). This technology 
is simple and elegant, ushered in the dawning of the most 
successful years in cardiovascular genetics and deciphering 
the genetic basis of single gene cardiovascular disorders, 
for example  hereditary cardiomyopathies, ion channel 
disorders, and autosomal-dominant hypercholesterolemia, 
among others.(95-99)
 Application of the massively parallel sequencing 
technology to genetic testing at the clinic, however, exposed 
even bigger challenges of how to interpret the findings 
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WGS
WGS detects the 3.2 billion bases of the human genome. The ability to sequence large cohorts is now 
a reality, and WGS will enable deeper understanding of the regulatory and other features in the human 
genome, as well as meaningful interpretations of whole genomes. WGS is also important for 
agriculture and microbial genomes.
De novo  sequencing
This method refers to sequencing of a novel genome for which there is no available reference 
sequence for alignment. The quality of the data depends on the size and continuity of the gaps in the 
data.
WES
WES captures only the protein coding part of the genome. Representing less than 2% of the human 
genome, WES is a cost-effective alternative to WGS. It is used for many applications, including 
investigating genetic disease, population genetics and cancer studies.
Transcriptome sequencing
This method creates a biological snapshot of expressed genes by capturing RNA and converting it to 
cDNA before sequencing. RNA sequencing can focus on mRNA, small RNA, noncoding RNA or 
microRNA, depending on the steps included befire cDNA synthesis.
Epigenome sequencing
Epigenome sequencing investigates heritable changes in gene activity caused by environmental factors, 
such as DNA methylation and acetylation, DNA-protein interactions, small RNA-mediated regulation 
and histone modifications.
PRECISION MEDICINE TOOLBOX
NGS platforms can answer questions related not only to the exome or genome but also the 
transcriptome and epigenome of any organism. Sequencing methods differ in terms of how samples 
are obtain and the data analysis involved.
Table 1. NGS methods.(92) (Adapted with permission from Nature).
and apply them to the care of the individual. The primary 
challenge has been identifying the causal variant(s) among 
4 million or so variants in each genome, including >12,000 
non-synonymous, and several hundred if not thousand 
putatively functional and pathogenic variants.(100,101) 
The plethora of the variants in each genome is inherent to 
the rare error rate of DNA replication machinery, which 
is estimated as well as empirically shown to be at 1×10−8 
per base.(102,103) Accordingly, ≈ 30 de novo variants are 
generated with each meiosis. The explosive growth of human 
population during the past millennium really presented an 
enormous challenge in human genetic diversity, as each 
birth contribute ≈ 30 new variants to the population genetic 
pool.(104) Variants with a minor allele frequency of <0.01, 
known as rare variants, are more common to be found in 
the population, compare to the common variants.(105) NGS 
systems are typically represented by SOLiD/Ion Torrent 
PGM from Life Sciences, Genome Analyzer/HiSeq 2000/
MiSeq from Illumina, and GS FLX Titanium/GS Junior 
from Roche. Wide application of this technology makes 
it possible to aid the achievement of goals to decode life 
mysteries, make better crops, detect pathogens, and improve 
life qualities.(106)
 DNA sequencing has evolved from Maxam-Gilbert 
and Sanger methods  in the 1970s to a set of technologies 
that  are collectively  referred  to as  NGS.(93,107-117) NGS 
sequences millions of short fragments of DNA in parallel, 
while the first generation perform just one DNA fragment 
at a time. Sequencing of DNA as a clinical test became 
routinely possible only after the automation of Sanger 
sequencing methods  introduced  in  the  mid-1990s,  which 
used capillary gel electrophoresis with fluorescence-based 
detection.(118,119) The throughput of NGS far surpasses 
that of automated Sanger sequencing. The higher throughput 
and lower per-base cost of NGS have contributed to its rapid 
adoption in clinical testing (120), despite the fact that several 
aspects of NGS analysis have much higher complexity.
 The NGS consolidates two processes: the analytic 
wet bench process and bioinformatics analysis of sequence 
data. The first component generally includes any or all of 
the following processes: patient samples handling, nucleic 
acids extraction, fragmentation, patient samples barcoding 
(molecular indexing), enrichment of targets for exome 
or gene panels, adapter ligation, amplification, library 
preparation, flow cell loading, and generation of sequence 
reads. Sequence generation is almost entirely automated and 
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the output consists of millions to billions of short sequence 
reads. The wet bench workflow is followed by intensive 
computational and bioinformatics analyses with application 
of variety of algorithms to map and align the short sequence 
reads to a linear reference human genome sequence. After 
mapping and alignment, variant calls are made at locations 
where nucleotides differ from the reference sequence. 
Due to the content needed, several separate processes then 
developed to analyze the clinical relevance of variants, 
either singly or in combination, related to their contribution 
to a given clinical phenotype.(121)
 The College of American Pathologist (CAP) NGS 
Work Group approached the analytic wet bench process 
and the bioinformatics or ‘‘dry bench’’ analyses as 2 
discrete processes requiring separate considerations for 
standards. The principles and guidelines (Supplementary 
Guidelines) developed by the Next-Generation Sequencing: 
Standardization of Clinical Testing (Nex-StoCT) 
workgroup. They represent the initial steps to perform a 
reliable and useful NGS-based test results related to clinical 
decision making. There are four components of quality 
management in clinical environment addressed in this 
guidelines: test validation, quality control procedures to 
assure and maintain accurate test results, the independent 
assessment of test performance through proficiency testing 
or alternative approaches and reference materials.(122)
 The translation of NGS from basic to clinical research 
and adoption for clinical diagnostics has occurred over a 
relatively short period of time. A growing number of clinical 
laboratories are implementing NGS-based diagnostic as- 
says, mostly in the form of multigene panels, although an 
increasing number of laboratories are performing exome 
and genome sequencing. CAP identified that the adoption 
of NGS by clinical laboratories required the development 
of accreditation requirements specific to NGS. To assist 
clinical laboratories with the validation of NGS methods 
and platforms, the ongoing monitoring of NGS testing to 
ensure quality results, and the interpretation and reporting 
of variants found using these technologies, the American 
College of Medical Genetics and Genomics has developed 
the following professional standards and guidelines.(123)
We are on the verge of the genomic era: doctors and 
patients will have access to genetic data to customize 
medical treatment. Consumers can already get 500,000-
1,000,000  variant    markers  analyzed  with   associated 
Bioinformatics
trait  information (124), and soon full genome sequencing 
will cost less than $1,000 (125). One group has performed 
a complete clinical  assessment  of  a  patient  using  a 
personal genome (126), and the 1,000 Genomes Project 
is sequencing 1,000 individuals (63). In the coming years, 
individual genomic data will inundate the bioinformatics 
world, and these will set other challenges the bioinformatics 
community needs to address. In the last decade, molecular 
science has made many advances to benefit medicine, 
including the Human Genome project, International HapMap 
project and genome wide association studies.(64) Single 
nucleotide polymorphisms (SNPs) are now recognized as 
the  main  cause of  human genetic variability  and  are 
already a valuable resource for mapping complex genetic 
traits.(127) Thousands of DNA variants have been identified 
that are  associated  with  diseases  and traits.(124) By 
combining these genetic associations with phenotypes  and 
drug response, personalized medicine will tailor treatments 
to the patients’  specific  genotype  (Figure 6).(40)
 Precision medicine associate the detailed, patient-
specific molecular information to diagnose and categorize 
disease, as  a  treatment  guide  to  improve  clinical 
outcome.(6) In  precision medicine, it is assumed that the 
underlying molecular causes of disease are at least partly 
specific to each patient, that is, each patient has a unique 
set of molecular alterations that are responsible for their 
disease condition. Identifying these molecular alterations 
Figure 6. Personalized medicine. Personal genomics connect 
genotype to phenotype and provide insight into disease. 
Pharmacogenomics connect genotype to patient-specific 
treatment.(40) (Adapted with permission from Oxford University 
Press).
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helps identify the best treatment for each individual, thus 
effectively tailoring and customizing treatment for each 
individual. In some diseases, precision medicine relies on 
molecular biomarkers, that is, molecular events that are 
correlated with treatment response and clinical outcome but 
not necessarily causal for the disease.(128)
 Currently, almost all precision medicine programs 
rely on NGS for patient’s DNA sample examination, range 
from highly focused to specific regions (a few genes are 
sequenced), to whole-exome (all genes are sequenced) 
and whole-genome (the entire genome is sequenced). The 
ability to interrogate a large number of genes is clinically 
relevant because predicting the efficacy of a growing 
number of drugs requires knowledge of more than one 
molecular alteration.(129) A frequently encountered hurdle 
in the implementation of a precision medicine program is 
the bioinformatics and informatics component required to 
support such a program.(130) Indeed, informatics plays 
a key role in nearly every aspect of a precision medicine 
program, ranging from physician-oriented clinical interfaces 
that enable them to order tests and visualize and interpret 
results for decision support and report generation, to 
systems for sample tracking and handling, data acquisition, 
and software for analyzing the genomic assays including 
identification and annotation of variants.(129)
 Bioinformatics is often defined as the application 
of computational techniques to understand and organize 
the information represents biological macromolecules. 
This unexpected union between the two subjects is largely 
attributed to the fact that life itself is an information 
technology; an organism’s physiology is largely determined 
by its genes, which at its most basic can be viewed as 
digital information. At the same time, there have been 
major advances in the technologies that supply the initial 
data.(131) The aims of bioinformatics are three-fold. First, 
at its simplest one, bioinformatics organizes data in a way 
that researchers can easily access existing information or 
submit new data entries, e.g., the Protein Data Bank for 3D 
macromolecular structures.(132,133) While data-curation is 
an essential task, the information stored in these databases 
is essentially useless until analyzed. Thus the purpose 
of bioinformatics extends much further. The second aim 
is developing tools and resources to perform faster data 
analysis. For example, sequencing a particular protein, or 
compare it with previously characterized sequences. This 
needs more than just a simple text-based search and programs 
such as FASTA format (134) and Position-Specific Iterative 
Basic  Local  Alignment  Search  Tool  (PSI-BLAST) (135) 
to  consider  what  comprises  a  biologically  significant 
match. Development of such resources required expertise in 
computational theory as well as a thorough understanding 
of biology. The third aim of these tools is to analyze the 
data and interpret the results in a biologically meaningful 
manner. Traditional biological studies examined individual 
systems in detail, then oftenly compared them with a few 
that are related. In bioinformatics, we now can perform 
a global analysis of all the available data and uncover 
common principles that apply across many systems and 
highlight novel features.(131)
 It may now cost less to sequence the three billion DNA 
base pairs of a human genome than to do a brain scan. But 
how to translate all that genomic data into treatment? The 
resulting era of “precision medicines” is already delivering 
treatments tailored to individual needs. These ‘big data’ 
efforts face huge challenges, from creating analytic tools and 
solving scientific puzzles to accessing millions of gigabytes 
of data and overcoming barriers to accessing patients’ health 
records.(136) Further advances in bioinformatics combined 
with experimental genomics for individuals are predicted to 
revolutionize the future of health care.
The completion of the first human genome sequence in 2003 
created much anticipation and promise among scientists, 
health care providers, media, and the public.(137) However, 
this did not result immediately in tangible changes in 
standard medical care. While the media continued to 
anticipate and the public keep waiting, genomic research 
progressed. Over the last few years, impressive strides have 
been made to this effect. In recent years, emerging evidence 
suggests a rapidly growing expectation to incorporate 
genomic medicine into individualized patient care.(138) The 
promise of genomic medicine, as one part of individualized 
care, is to enable medical practitioners to make better 
clinical decisions through an improved informed process. 
The anticipated results are to improve targeted therapies, 
reduce side-effects, increase prevention and prediction 
of disease, enable earlier disease intervention, reduce 
healthcare costs and improve patient outcomes.(139) A 
human ‘cancer genome’, or oncogenome, is a residential 
for numerous chromosomes, chromatin (the fibers that 
constitute the chromosomes) and nucleotides alterations. 
These include irreversible aberrations in the sequence or 
structures of DNA, genes or chromosomes (that is, the copy 
number of the DNA). They could also include potentially 
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reversible changes, known as epigenetic modifications to 
the DNA and/or to the histone proteins, which are closely 
associated with the DNA in chromatin. These reversible and 
irreversible changes affect hundreds to thousands of genes 
and/or regulatory transcripts. Collectively, they result in the 
activation or inhibition of various biological events, thereby 
causing aspects of cancer pathophysiology, including 
angiogenesis, immune evasion, metastasis, and  altered  cell 
growth,  death  and  metabolism.(140,141) The baseline 
information about frequent genomic alterations in cancer 
generated in the research setting by sequencing the DNA 
of thousands of tumors is now being coupled with NGS-
based methods that rapidly generate the mutational profile 
of a cancer genome in the clinical setting to inform genome-
guided cancer medicine.(142) 
 Insights into the molecular pathology of disease are 
creating opportunities for the development of therapies with 
durable clinical benefit while challenging existing model 
of therapeutic development and clinical care.(141,143,144) 
Large international consortia, such as the ICGC (145,146), 
are mapping the genomes of thousands of cancers to 
identify opportunities  for  prevention,  early  detection  and 
treatment (147). Although genomics is leading the way, high-
throughput proteomics and metabolomics are following 
closely behind.(148) These methodological advances have 
ushered in a target specific molecular processes new era of 
therapeutics. Though there have been some successes, the 
overall strategy remains in its infancy.(149-159) The central 
premise of precision medicine is that matching a drug and 
its mechanism of action using a marker to select patients, a 
process often referred to as matching the right drug to the 
right patient, can offer greater potential for durable clinical 
benefits.(160)
 Metabolomics allows for a global assessment 
of a cellular state within the context of the immediate 
environment, taking into account genetic regulation, altered 
kinetic activity of enzymes, and changes in metabolic 
reactions.(161-163) Thus, compared with genomics or 
proteomics, metabolomics reflects changes in phenotype 
and therefore function. The omic sciences are, however, 
complementary as ‘‘upstream’’ changes in genes and 
proteins are measured ‘‘downstream’’ as changes in cellular 
metabolism.(161,164). Other features of metabolomics 
are similar to those of proteomics and transcriptomics, 
including the ability to assay biofluids or tumor samples and 
the relatively inexpensive, rapid, and automated techniques 
once start-up costs are taken into account.(165)
 Personalized approaches reach the full spectrum 
of cancer care. Personalized risk assessment can provide 
patients identification at greatest risk of developing specific 
cancers, so they can be offered more comprehensive 
screening and prevention strategies, which will lead to fewer 
cases of invasive cancer, earlier diagnoses, and improved 
outcomes.(166) Personalized medicine has potential to 
change the standard of care for cardiovascular diseases. 
Although there is only a few examples of personalized 
cardiovascular medicine based on molecular profiling exist 
to date, while other methods have been used. Certainly, 
normalization of drug exposure across different subsets of 
individuals is one form of personalized medicine that is well 
established. The development of personalized medicine 
strategies based on genetic or physiological biomarkers for 
cardiovascular diseases such as atherosclerosis, heart failure 
and hypertension is challenging because of the multifactorial 
etiology of these diseases.(4)
 Cardiovascular diseases originate from the confluence 
of many different factors. Genetic factor plays only a weak 
effect on the process taken as a whole, but it may substantially 
influence one of the known underlying pathways. For 
example, genetic effects on lipid biomarkers may often 
be more readily detected than their effect on myocardial 
infarction.(101) Genetic linkage analysis in large families, 
which led to deciphering the molecular genetic basis of 
single gene disorders, such as hereditary cardiomyopathies 
and ion channel disorders (95,97,168,169), continues to 
offer a robust platform for identification of the causal 
genes for single gene disorders. Signal-transducing adaptor 
protein 1 (STAP1), encoding signal transducing adaptor 
family member 1, was mapped recently as a novel gene for 
autosomal dominant familial hypercholesterolemia through 
linkage analysis.(169) Further characterization of the locus 
after exome sequencing and showing evidence of enrichment 
of STAP1 variants in an independent cohort with familial 
hypercholesterolemia supported the causal role of STAP1 
in autosomal dominant familial hypercholesterolemia. 
Thus, STAP1 joins the previously identified  low-density 
lipoprotein receptor (LDLR), apolipoprotein B (APOB), and 
proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, 
as the fourth causal  gene  associated  with  this  rare  single 
gene disorder.(98,170,171) The genetic cardiomyopathies 
present a window  to  cardiac  pathophysiology  when discrete 
cellular pathways are disrupted. Over the past decades, the 
role of numerous proteins in triggering cardiomyopathy 
and hence HF has finally become clear. Despite the genetic 
complexity, direct application of genetic testing is now a 
mainstay in managing affected families, and scientifically 
and clinically useful themes are emerging that should lead 
to improved treatment.(95)
 141
Personalized Medicine: The Future of Health Care (Meiliana A, et al.)Indones  Biomed J. 2016; 8(3): 127-46DOI: 10.18585/inabj.v8i3.271
 Investigations of rare monogenic disorders of 
heart rhythm has elucidated the fundamental molecular 
and genetic mechanisms of sickle cell disease. After 
identification of more than 25 causal genes, there remain 
many subjects with inherited arrhythmia susceptibility but 
do not have mutations, this suggests that there is still other 
genes left unidentified. Newer strategies such as exome 
and WGS may be valuable to uncover additional molecular 
etiologies. Efforts to understand mechanisms responsible for 
incomplete penetrance, including identification of modifier 
genes, will also contribute to deciphering the complex 
relationships between genotype and phenotype.(97)
 In diabetes, personalized medicine refers to utilize the 
patients specific characters for most effective diagnostic or 
treatment strategies. These include individual behavioral 
and phenotypic features, standard clinical laboratory 
findings, and gene  sequences  and  other molecular 
markers.(172) Diabetes mellitus has long been recognized 
to be a complex, heterogeneous  disorder, especially in 
type 2 diabetes patients with substantial variability in 
genetic risk factors, underlying pathogenic mechanisms, 
and clinical features. Therefore it represents a human 
disease that gains a substantial benefit from personalized 
approaches to treatment. Nevertheless, patients with type 2 
diabetes often are treated similarly, with little consideration 
of individual characteristics that might  affect clinical 
outcome and therapeutic response.(173) Both type 1 and 
type 2 diabetes are thought to be complex diseases, which 
means they need the interplay of numerous susceptibility 
and protective genes, acting in concert with negative and 
positive environmental factors to be developed.(174) 
 Type 2 diabetes typically is characterized by a 
combination of abnormalities in both insulin secretion and 
responsiveness, plus  a  more  gradual and less extensive 
loss of β-cell secretory capacity than occurs in type 1 
diabetes. For this reason, a spectrum of pharmacologic 
agents with actions that include augmentation of insulin 
sensitivity, stimulation of insulin secretion, and slowing 
of intestinal glucose absorption. Should be the available 
options for glycemic management in type 2 diabetes and 
not only exogenous insulin.(173,174) The application of 
systems biology methods to complex diseases such as 
diabetes mellitus  is   now  being  explored  as  a  strategy 
for  amplifying insights into pathophysiology and disease 
management by integrating the expanding amount of 
molecular data.(175,176) It is likely that personalized 
medicine in more common forms of diabetes can have 
substantial benefit by similarly using individual patient 
characteristics to define a preferred sequence of options 
in treatment rather than one specific therapy.(172) New 
technology in human genetics transformation become the 
single best hope to innovate and improve clinical success 
rates in drug development.
Technologies for monitoring individuals’ health are 
becoming increasingly available, especially with consumer 
electronic devices moving into health measurements. 
The devices currently measure mostly vital signs, but it 
is inevitable they will move into blood tests and portable 
imaging in the future. The real ambition of personalized 
medicine said Goldstein, “is in transforming the way we 
develop new medicines.” He also believes that “other 
technological drivers will be in genome editing and stem 
cell biology, since they together create a clear pathway 
for in vitro models of many human diseases.” It is this 
deep appreciation for the unique genetic and phenotypic 
characteristics of an individual that is elegantly depicted by 
Sir William Osler famous quote: The good physician treats 
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Automated semantic annotation of rare disease cases: a case study. 
Database (Oxford). 2014; 2014 pii: bau045. doi: 10.1093/database/
bau045.
46. Kuleshov V, Xie D, Chen R, Pushkarev D, Ma Z, Blauwkamp T, 
et al. Whole-genome haplotyping using long reads and statistical 
methods. Nat Biotechnol. 2014; 32: 261-6. 
47. Welch KO, Marin RS, Pandya A, Arnos KS. Compound heterozygosity 
for dominant and recessive GJB2 mutations: effect on phenotype 
and  review  of  the  literature. Am J Med Genet A. 2007; 143A: 
1567-73. 
48. Fong CYI, Mumford AD, Likeman MJ, Jardine PE. Cerebral palsy in 
siblings caused by compound heterozygous mutations in the gene 
encoding protein C. Dev Med Child Neurol. 2010; 52: 489-93. 
 143
Personalized Medicine: The Future of Health Care (Meiliana A, et al.)Indones  Biomed J. 2016; 8(3): 127-46DOI: 10.18585/inabj.v8i3.271
49. Shimizu H, Takizawa Y, Pulkkinen L, Murata S, Kawai M, Hachisuka 
H,  et al. Epidermolysis bullosa simplex associated with muscular 
dystrophy: phenotype-genotype correlations and review of the 
literature. J Am Acad Dermatol. 1999; 41: 950-6. 
50. Tewhey R, Bansal V, Torkamani A, Topol EJ, Schork NJ. The 
importance of phase information for human genomics. Nat Rev 
Genet. 2011; 12: 215-23. 
51. Browning SR, Browning BL. Haplotype phasing: existing methods 
and new developments. Nat Rev Genet. 2011; 12: 703-14. 
52. Kitzman JO, Mackenzie AP, Adey A, Hiatt JB, Patwardhan RP, 
Sudmant PH, et al. Haplotype-resolved genome sequencing of a 
Gujarati Indian individual. Nat Biotechnol. 2011; 29: 59-63. 
53. Fan HC, Wang J, Potanina A, Quake SR. Whole-genome molecular 
haplotyping of single cells. Nat Biotechnol. 2011; 29: 51-7. 
54. Green RE,  Krause J, Briggs AW, Maricic T, Stenzel U, Kircher M, et 
al. A draft sequence of the Neandertal genome. Science. 2010; 328: 
710-22. 
55. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, 
et al. Initial sequencing and analysis of the human genome. Nature. 
2001; 409: 860-921. 
56. Li R, Li Y, Fang X, Yang H, Wang J, Kristiansen K, et al. SNP 
detection for massively parallel whole-genome resequencing. 
Genome Res. 2009; 19: 1124-32. 
57. Li H, Durbin R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics. 2009; 25: 1754-60. 
58. DePristo MA,  Banks E, Poplin R, Garimella KV, Maguire JR, Hartl 
C, et al. A framework for variation discovery and genotyping using 
next-generation DNA sequencing data. Nat Genet. 2011; 43: 491-8. 
59. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, et al. The 
diploid genome sequence of an individual human. PLoS Biol. 2007; 
5: e254. doi: 10.1371/journal.pbio.0050254.
60. Wang J, Wang W, Li R, Li Y, Tian G, Goodman L, et al. The diploid 
genome sequence of an Asian individual. Nature. 2008; 456: 60-5. 
61. Ahn SM, Kim TH, Lee S, Kim D, Ghang H, Kim DS, et al. The first 
Korean genome sequence and analysis: full genome sequencing for 
a socio-ethnic group. Genome Res. 2009; 19: 1622-9. 
62. Tong P, Prendergast JG, Lohan AJ, Farrington SM, Cronin S, Friel N, 
et al. Sequencing and analysis of an Irish human genome. Genome 
Biol. 2010; 11: R91. 
63. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton 
A, Brooks LD, Durbin RM, et al. A map of human genome variation 
from population-scale sequencing. Nature. 2010; 467: 1061-73. 
64. International HapMap Consortium. A haplotype map of the human 
genome. Nature. 2005; 437: 1299-320. 
65. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks 
LD, DePristo MA, Durbin RM, et al. An integrated map of genetic 
variation from 1,092 human genomes. Nature. 2012; 491: 56-65. 
66. Cao H, Wu H, Luo R, Huang S, Sun Y, Tong X, et al. De Novo 
assembly of a haplotype-resolved human genome. Nat Biotechnol. 
2015; 33: 617-22. 
67. Browning SR, Browning BL. Rapid and accurate haplotype phasing 
and missing-data inference for whole-genome association studies 
by use of localized haplotype clustering. Am J Hum Genet. 2007; 
81: 1084-97. 
68. Duitama J, McEwen GK, Huebsch T, Palczewski S, Schulz S, 
Verstrepen K, et al. Fosmid-based whole genome haplotyping of 
a HapMap trio child: evaluation of single individual haplotyping 
techniques. Nucleic Acids Res. 2012; 40: 2041-53. 
69. Woolley AT, Guillemette C, Li Cheung C, Housman DE, Lieber CM. 
Direct haplotyping of kilobase-size DNA using carbon nanotube 
probes. Nat Biotechnol. 2000; 18: 760-3. 
70. Cao H, Wang Y, Zhang W, Chai X, Zhang X, Chen S, et al. A short-
read multiplex sequencing method for reliable, cost-effective and 
high-throughput genotyping in large-scale studies. Hum Mutat. 
2013; 34: 1715-20. 
71. Dapprich J, Ferriola D, Magira EE, Kunkel M, Monos D. SNP-
specific extraction of haplotype-resolved targeted genomic regions. 
Nucleic Acids Res. 2008; 36: e94. doi: 10.1093/nar/gkn345.
72. Suk EK, McEwen GK, Duitama J, Nowick K, Schulz S, Palczewski 
S, et al. A comprehensively molecular haplotype-resolved genome 
of a European individual. Genome Res. 2011; 21: 1672-85. 
73. ABPI. The stratification of disease for personalised medicines: 
Research driven recommendations to strengthen a unified UK 
strategy through a stakeholder alliance. London: The Association of 
the British Pharmaceutical Industry; 2014. 
74. [N.A.]. The coming era of human phenotyping. Nat Biotechnol. 2015; 
6: 567. doi: 10.1038/nbt.3266.
75. Relling MV, Evans WE. Pharmacogenomic in the clinic. Nature. 
2015; 526: 343-50. 
76. Kinch MS, Haynesworth A, Kinch SL, Hoyer D. An overview of 
FDA-approved new molecular entities: 1827-2013. Drug Discov 
Today. 2014; 19: 1033-9. 
77. Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena 
A, et al. Pharmacogenomic information in drug labels: European 
Medicines Agency perspective. Pharmacogenomics J. 2015; 15: 
201-10. 
78. Ishiguro A, Yagi S, Uyama Y. Characteristics of pharmacogenomics/ 
biomarker-guided clinical trials for regulatory approval of anti-
cancer drugs in Japan. J Hum Genet. 2013; 58: 313-6. 
79. U.S. Food and Drug Administration [Internet]. Table of 
Pharmacogenomic Biomarkers in Drug Labeling [updated 2016 Jul 
11, cited 2016 Jul 29]. Available from: http://www.fda.gov/drugs/
scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
80. CPIC (Clinical Pharmacogenetics Implementation Consortium) 
[Internet]. Genes – Drugs [updated 2016 May 13; cited 2016 Jul 
29]. Available from: https://cpicpgx.org/genes-drugs/.
81. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel 
U, Howard SC, et al. Preemptive clinical pharmacogenetics 
implementation: current programs in five US medical centers. Annu 
Rev Pharmacol Toxicol. 2015; 55: 89-106. 
82. Buchanan J, Wordsworth S, Schuh A. Issues surrounding the health 
economic evaluation of genomic technologies. Pharmacogenomics. 
2013; 14: 1833-47. 
83. Schroeder SA, Frist W. Phasing out fee-for-service payment. N Engl 
J Med. 2013; 368: 2029-32. 
84. Levy KD, Decker BS, Carpenter JS, Flockhart DA, Dexter PR, 
Desta Z, et al. Prerequisites to implementing a pharmacogenomics 
program in a large health-care system. Clin Pharmacol Ther. 2014; 
96: 307-9. 
85. Gordon AS, Tabor HK, Johnson AD, Snively BM, Assimes TL, 
Auer PL, et al. Quantifying rare, deleterious variation in 12 human 
cytochrome P450 drug-metabolism genes in a large-scale exome 
dataset. Hum Mol Genet. 2014; 23: 1957-63.
86. Chen Z, Liew D, Kwan P. Effects of a HLA-B*15:02 screening policy 
on antiepileptic drug use and severe skin reactions. Neurology. 
2014; 83: 2077-84.
87. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church 
DM, et al. ClinVar: public archive of relationships among sequence 
variation and human phenotype. Nucleic Acids Res. 2014; 42: 
D980-5. 
88. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum 
MJ, et al. ClinGen -- the Clinical Genome Resource. N Engl J Med. 
2015; 372: 2235-42. 
144
The Indonesian Biomedical Journal, Vol.8, No.3, December 2016, p.127-46 Print ISSN: 2085-3297, Online ISSN: 2355-9179
89. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, 
Thorn CF, et al. Pharmacogenomics knowledge for personalized 
medicine. Clin Pharmacol Ther. 2012; 92: 414-7. 
90. Carter RF. Adapting next generation technologies to clinical 
molecular oncology service. Clin Lab News. 2015; 2015: 22-8. 
91. Dorschner MO, Amendola LM, Shirts BH, Kiedrowski L, Salama 
J, Gordon AS, et al. Refining the structure and content of clinical 
genomic reports. Am J Med Genet C Semin Med Genet. 2014; 1: 
85-92. 
92. Brazil M. Genomics technologies march into new markets. Med 
Tech Deal Makers. P:M8. Available from: http://www.nature.com/
medtechdealmakers.
93. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-
terminating inhibitors. Proc Natl Acad Sci USA. 1977; 74: 5463-7. 
94. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et 
al. The sequence of the human genome. Science. 2001; 291: 1304-
51. 
95. Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing 
heart failure. Circ Res. 2013; 113: 660-75. 
96. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers 
M, et al. Mutations in PCSK9 cause autosomal dominant 
hypercholesterolemia. Nat Genet. 2003; 34: 154-6. 
97. George AL Jr. Molecular and genetic basis of sudden cardiac death. J 
Clin Invest. 2013; 123: 75-83. 
98. Marian AJ. Recent developments in cardiovascular genetics and 
genomics. Circ Res. 2014; 115: e11-7. 
99. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. 
Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 
2014; 115: 115-30. 
100. Marian AJ. Medical DNA sequencing. Curr Opin Cardiol. 2011; 26: 
175-80. 
101. Marian AJ, Belmont J. Strategic approaches to unraveling genetic 
causes of cardiovascular diseases. Circ Res. 2011; 108: 1252-69. 
102. Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson 
G, et al. Rate of de novo mutations and the importance of father’s 
age to disease risk. Nature. 2012; 488: 471-5. 
103. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton 
A, Brooks LD, Durbin RM, at al. A map of human genome variation 
from population-scale sequencing. Nature. 2010; 467: 1061-73. 
104. Keinan A, Clark AG. Recent explosive human population growth has 
resulted in an excess of rare genetic variants. Science. 2012; 336: 
740-3. 
105. Marian AJ. The bottleneck in genetic testing. Circ Res. 2015; 117: 
586-8. 
106. Liu L, Li Y, Li S, Hu N, He Y, Pong R, et al. Comparison of next-
generation sequencing systems. J Biomed Biotechnol. 2012; 2012: 
251364. doi: 10.1155/2012/251364.
107. Maxam AM, Gilbert W. A new method for sequencing DNA. Proc 
Natl Acad Sci USA. 1977; 74: 560-4. 
108. Sanger F, Coulson AR. A rapid method for determining sequences in 
DNA by primed synthesis with DNA polymerase. J Mol Biol. 1975; 
94: 441-8. 
109. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, 
Brown CG, et al. Accurate whole human genome sequencing using 
reversible terminator chemistry. Nature. 2008; 456: 53-9. 
110. Mardis ER. The impact of next-generation sequencing technology on 
genetics. Trends Genet. 2008; 24: 133-41. 
111. Mardis ER. Next-generation DNA sequencing methods. Annu Rev 
Genomics Hum Genet. 2008; 9: 387-402. 
112. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben 
LA, et al. Genome sequencing in microfabricated high-density 
picolitre reactors. Nature. 2005; 437: 376-80. 
113. Metzker ML. Sequencing technologies: the next generation. Nat Rev 
Genet. 2010; 11: 31-46. 
114. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey 
M, et al. An integrated semiconductor device enabling non-optical 
genome sequencing. Nature. 2011; 475: 348-52. 
115. Schuster SC. Next-generation sequencing transforms today’s biology. 
Nat Methods. 2008; 5: 16-8. 
116. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 
2008; 26: 1135-45.
117. Valouev A, Ichikawa J, Tonthat T, Stuart J, Ranade S, Peckham H, 
et al. A high-resolution, nucleosome position map of C. elegans 
reveals a lack of universal sequence-dictated positioning. Genome 
Res. 2008; 18: 1051-63. 
118. Hutchison CA 3rd. DNA sequencing: bench to bedside and beyond. 
Nucleic Acids Res. 2007; 35: 6227-37. 
119. Metzker ML. Emerging technologies in DNA sequencing. Genome 
Res. 2005; 15: 1767-76. 
120. Mardis ER. A decade’s perspective on DNA sequencing technology. 
Nature. 2011; 470: 198-203. 
121. Aziz N, Zhao Q, Bry L, Driscoll D, Funke B, Gibson JS, et al. College 
of American Pathologists’ laboratory standards for next-generation 
sequencing clinical tests. Arch Pathol Lab Med. 2015; 139: 481-93. 
122. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch 
T, et al. Assuring the quality of next-generation sequencing in 
clinical laboratory practice. Nat Biotechnol. 2012; 30: 1033-6. 
123. Rehm HD, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, 
Deignan JL, et al. ACMG clinical laboratory standards for next-
generation sequencing. Gen Med. 2013; 15: 733-47. 
124. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, 
Collins FS, et al. Potential etiologic and functional implications of 
genome-wide association loci for human diseases and traits. Proc 
Natl Acad Sci USA. 2009; 106: 9362-7. 
125. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani 
BG, et al. Human genome sequencing using unchained base reads 
on self-assembling DNA nanoarrays. Science. 2010; 327: 78-81. 
126. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, et 
al. Clinical assessment incorporating a personal genome. Lancet. 
2010; 375: 1525-35. 
127. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: 
cataloging human DNA sequence variation. Science. 1997; 278, 
1580-1. 
128. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda 
R, et al. A panel of four miRNAs accurately differentiates malignant 
from benign indeterminate thyroid lesions on fine needle aspiration. 
Clin Cancer Res. 2012; 18: 2032-8. 
129. Sboner A, Elemento O. A primer on precision medicine informatics. 
Brief Bioinform. 2016; 17: 145-53. 
130. Servant N, Romejon J, Gestraud P, La Rosa P, Lucotte G, Lair S, et al. 
Bioinformatics for precision medicine in oncology: principles and 
application to the SHIVA clinical trial. Front Genet. 2014; 5: 152. 
doi: 10.3389/fgene.2014.00152.
131. Luscombe NM, Greenbaum D, Gerstein M. What is bioinformatics? 
An introduction and overview. Yearb Med Inform. 2001; 2001: 83-
100. 
132. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr, Brice MD, 
Rodgers JR, et al. The Protein Data Bank. A computer-based 
archival file for macromolecular structures. Eur J Biochem. 1977; 
80: 319-24. 
133. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, 
et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28: 235-42. 
134. Pearson WR, Lipman DJ. Improved tools for biological sequence 
comparison. Proc Natl Acad Sci USA. 1988; 85: 2444-8. 
 145
Personalized Medicine: The Future of Health Care (Meiliana A, et al.)Indones  Biomed J. 2016; 8(3): 127-46DOI: 10.18585/inabj.v8i3.271
135. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, 
et al. Gapped BLAST and PSI-BLAST: a new generation of protein 
database search programs. Nucleic Acids Res. 1997; 25: 3389-402. 
136. Bender E. Big data in biomedicine. Nature. 2015; 527: S1. doi: 
10.1038/527s1a.
137. Green ED, Guyer MS, National Human Genome Research I. Charting 
a course for genomic medicine from base pairs to bedside. Nature. 
2011; 470: 204-13. 
138. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, 
Wilson R, et al. Implementing genomic medicine in the clinic: The 
future is here. Genet Med. 2013; 15: 258-67. 
139. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, 
Borad MJ, Bryce AH, et al. Implementing individualized medicine 
into the medical practice. Am J Med Gen C Semin Med Genet. 
2014; 166C: 15-23
140. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 
57-70. 
141. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, 
Collins FS, et al. Potential etiologic and functional implications of 
genome-wide association loci for human diseases and traits. Proc 
Natl Acad Sci USA. 2009; 106: 9362-7. 
142. Chin L, Gray JW. Translating insights from the cancer genome into 
clinical practice. Nature. 2008; 452: 553-63. 
143. Andre F, Mardis E, Salm M, Soria JC, Siu LL, Swanton C. Prioritizing 
targets for precision cancer medicine. Ann Oncol. 2014; 25: 2295-
303. 
144. Stratton MR. Exploring the genomes of cancer cells: progress and 
promise. Science. 2011; 331: 1553-8. 
145. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 
2009; 458: 719-24. 
146. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, et 
al. International network of cancer genome projects. Nature. 2010; 
464: 993-8. Erratum in: Nature. 2010; 465: 966. 
147. The Cancer Genome Atlas Research Network. Comprehensive 
genomic characterization defines human glioblastoma genes and 
core pathways. Nature. 2008; 455: 1061-8. Erratum in: Nature. 
2013; 494: 506. 
148. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery 
science to personalized medicine. Nature Med. 2011; 17: 297-303. 
149. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, et al. Proteogenomic 
characterization of human colon and rectal cancer. Nature. 2014; 
513: 382-7. 
150. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, 
et al. Progression-free survival in gastrointestinal stromal tumours 
with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-
34
151. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: 
from discovery to therapy in record time. Cancer Cell. 2010; 18: 
548-51
152. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber 
JS, et al. Survival in BRAF V600-mutant advanced melanoma 
treated with vemurafenib. N Engl J Med. 2012; 366: 707-14. 
153. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, 
et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl 
J Med. 2011; 365: 1273-83
154. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. 
Crizotinib versus chemotherapy in advanced ALK-positive lung 
cancer. N Engl J Med. 2013; 368: 2385-94. 
155. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe 
H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer 
with mutated EGFR. N Engl J Med. 2010; 362: 2380-8. 
156. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin 
G, et al. Olaparib maintenance therapy in patients with platinum-
sensitive relapsed serous ovarian cancer: a preplanned retrospective 
analysis of outcomes by BRCA status in a randomised phase 2 trial. 
Lancet Oncol. 2014; 15: 852-61. 
157. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, 
Wistuba II, et al. Using multiplexed assays of oncogenic drivers in 
lung cancers to select targeted drugs. J Am Med Assoc. 2014; 311: 
1998-2006. 
158. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, 
et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung 
cancer. N Engl J Med. 2015; 372: 1689-99. 
159. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, 
Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib 
mesylate in advanced gastrointestinal stromal tumors. N Engl J 
Med. 2002; 347: 472-80. 
160. Green ED, Guyer MS, National Human Genome Research Institute. 
Charting a course for genomic medicine from base pairs to bedside. 
Nature. 2011; 470: 204-13. 
161. Blankin AV, Piantadosi S, Hollingsworth SI. Patient-centric trials for 
therapeutic development in precision oncology. Nature. 2015; 526: 
361-70. 
162. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev 
Cancer. 2004; 4: 551-61. 
163. Mendes P, Kell DB, Westerhoff HV. Why and when channeling can 
decrease pool size at constant net flux in a simple dynamic channel. 
Biochim Biophys Acta. 1996; 1289: 175-86. 
164. Mendes P, Kell DB, Westerhoff HV. Channelling can decrease pool 
size. Eur J Biochem. 1992; 204: 257-66. 
165. Boros LG, Lerner MR, Morgan DL, Taylor SL, Smith BJ, Postier RG, 
et al. [1,2-13C2]-D-glucose profiles of the serum, liver, pancreas, 
and DMBA-induced pancreatic tumors of rats. Pancreas. 2005; 31: 
337-43. 
166. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of 
metabolomics in oncology: a review. Clin Cancer Res. 2009; 15: 
431-40. 
167. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills B. Building a 
personalized medicine infrastructure at a major cancer center. J Clin 
Oncol. 2013; 31: 1849-57. 
168. Cerrone M, Napolitano C, Priori SG. Genetics of ion-channel 
disorders. Curr Opin Cardiol. 2012; 27: 242-52. 
169. Moore JR, Leinwand L, Warshaw DM. Understanding cardiomyopathy 
phenotypes based on the functional impact of mutations in the 
myosin motor. Circ Res. 2012; 111: 375-85. 
170. Fouchier SW, Dallinga-Thie GM, Meijers JC, Zelcer N, Kastelein 
JJ, Defesche JC, et al. Mutations in STAP1 are associated with 
autosomal dominant hypercholesterolemia. Circ Res. 2014; 115: 
552-5. 
171. Simino J, Kume R, Kraja AT, Turner ST, Hanis CL, Sheu WH, et 
al. Linkage analysis incorporating gene-age interactions identifies 
seven novel lipid loci: the Family Blood Pressure Program. 
Atherosclerosis. 2014; 235: 84-93. 
172. Rosenthal EA, Ranchalis J, Crosslin DR, Burt A, Brunzell JD, 
Motulsky AG, et al. Joint linkage and association analysis with 
exome sequence data implicates SLC25A40 in hypertriglyceridemia. 
Am J Hum Genet. 2013; 93: 1035-45. 
173. Malandrino N, Smith RJ. Peronalized medicine in diabetes. Clin 
Chem. 2011; 57: 231-40.
174. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter 
JI. Individualizing therapies in type 2 diabetes mellitus based on 
patient characteristics: what we know and what we need to know. J 
Clin Endocrinol Metab. 2010; 95: 1566-74. 
146
The Indonesian Biomedical Journal, Vol.8, No.3, December 2016, p.127-46 Print ISSN: 2085-3297, Online ISSN: 2355-9179
175. Muller G. Personalized prognosis and diagnosis of type 2 diabetes: 
vision or fiction? Pharmacology. 2010; 85: 168-87. 
176. Wolkenhauer O, Fell D, De Meyts P, Bluthgen N, Herzel H, Le 
Novere N, et al. SysBioMed report: advancing systems biology for 
medical applications. IET Syst Biol. 2009; 3: 131-6. 
177. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new 
technologies enable predictive and preventative medicine. Science. 
2004; 306: 640-3. 
